Latest news with #ArteloBiosciences
Business Insider
2 days ago
- Business
- Business Insider
Artelo Biosciences Inc trading halted, news pending
19:50 EDT Artelo Biosciences (ARTL) Inc trading halted, news pending Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
05-06-2025
- Health
- Yahoo
Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study
SOLANA BEACH, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced its presentation of new data at the British Pain Conference held in Newport, Wales, UK on June 3-5, 2025 ( that further validates the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating osteoarthritis (OA) pain. Professor Saoirse O'Sullivan, Vice President of Translation Sciences at Artelo Biosciences, presented results from an animal study titled: 'The Fatty Acid Binding Protein 5 Inhibitor ART26.12 is a Novel Analgesic for Osteoarthritis Pain.' The data builds upon an extensive set of pre-clinical data for ART26.12 that demonstrates analgesic and anti-nocicpetive effects in multiple models of pain. Positive effects of ART26.12 were observed in a surgical rat model of osteoarthritis, in which either single or repeated oral doses of Artelo's FABP5 inbitor increased the ability of rats to bear weight on the limb with OA out to four weeks. Professor O'Sullivan stated, 'ART26.12 was effective in a dose-responsive manner, with sustained and consistent effects over 28 days. The analgesic effect of ART26.12 was similar to naproxen, a proven first-line therapy which is often hampered by a number of serious side effects when taken chronically.' Now undergoing human trials, ART26.12 is a novel, non-opioid, non-steroidal drug candidate initially in development for the prevention and treatment of peripheral neuropathy caused by common chemotherapy treatments with potential for development as an alternative for chronic OA pain. OA is a progressive joint disease in which cartilage wears away over time, causing chronic pain, stiffness, swelling, and significant loss of mobility, especially in the knees, hips, hands, and spine. It affects approximately 606.9 million people globally, including over 32 million in the U.S., and can lead to disabling pain, reduced quality of life, and loss of independence, especially in advanced cases. About ART26.12 ART26.12, Artelo's lead FABP5 inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. Data from the first Phase 1 trial with ART26.12 is anticipated in Q2 2025. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). FABPs are a family of intracellular proteins that chaperone lipids important to normal cellular function. FABP is overexpressed and associated with abnormal lipid signaling in several pathologies. In addition to ART26.12 in CIPN, Artelo's extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders. About Artelo Biosciences Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at and X: @ArteloBio. Forward Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, efficacy of the Company's product candidates, results and conclusions from preclinical studies and clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, 'expect,' 'anticipate,' 'intend,' 'plan,' 'believe,' 'estimate,' 'potential,' 'predict,' 'project,' 'should,' 'would' and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws. Investor Relations Contact:Crescendo Communications, LLCTel: 212-671-1020Email: ARTL@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-04-2025
- Business
- Yahoo
EXCLUSIVE: Artelo Biosciences' New Peer-Reviewed Research Shows Effectiveness Of Psoriasis Candidate In Animal Models
Artelo Biosciences, Inc. (NASDAQ:ARTL) on Monday announced new research published in the peer-reviewed Journal of Investigative Dermatology describing the positive effects of ART26.12 in both in vitro and in vivo psoriasis models. The research shows results comparable to immunomodulatory drugs with known serious adverse events. The research highlights ART26.12, Artelo's orally active, small-molecule inhibitor of Fatty Acid Binding Protein 5 (FABP5), and its potential ability to treat Warren, PhD, Lead Author and Principal Scientist at Artelo, said, 'We are excited to share the results on this novel target in psoriasis. Our findings demonstrate that ART26.12 has effects comparable to powerful immunomodulators, while its unique pharmacology leads to a significantly distinct expression of proteins and lipids in the skin.' Dr. Warren added, 'Pre-clinical IND-enabling studies with ART26.12, supported by a literature review of greater than 300 studies examining FABP inhibition, imply a low toxicological risk for ART26.12, which, if borne out in clinical studies, suggest FABP5 inhibition with an orally delivered small molecule may be an attractive, less costly, and safer approach for treating this debilitating chronic disease.' A Phase 1 Single Ascending Dose study in healthy volunteers with ART26.12 has completed enrollment, and data announcements are expected in the second quarter of 2025. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). In addition to ART26.12 in CIPN, Artelo's extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders. In January, Artelo Biosciences completed a safety review of the first cohort of eight healthy volunteers in the company's Phase 1 study of ART26.12. In December, Artelo Biosciences announced the presentation of preliminary data on ART27.13, a benzimidazole derivative being studied for cancer-related anorexia. Artelo is evaluating ART27.13 in the Phase 1/2 trial in cancer-related anorexia, which is currently enrolling Phase 2 of the study. In Phase 1, ART27.13 was orally administered at 150 to 650 microgram doses. The investigational drug was well tolerated, with only mild to moderate adverse events observed in a minority of participants. At one month of treatment, two-thirds of participants showed evidence that the drug was impacting their weight loss, with either stabilization or reversal of weight loss associated with their cancer. Phase 2 is accruing participants at a 650 microgram dosage with planned escalation at 4-week intervals up to a dose of 1300 micrograms per day. Initial data from the Phase 2 CAReS trial is anticipated by the end of Q2 2025. Price Action: ARTL stock closed at $1.04 on Friday. Read Next:UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article EXCLUSIVE: Artelo Biosciences' New Peer-Reviewed Research Shows Effectiveness Of Psoriasis Candidate In Animal Models originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Globe and Mail
07-03-2025
- Health
- Globe and Mail
Cancer Anorexia Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports
The Key Cancer Anorexia Companies in the market include - Helsinn Healthcare, Artelo Biosciences, NGM Biopharmaceuticals, and others. DelveInsight's 'Cancer Anorexia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cancer Anorexia, historical and forecasted epidemiology as well as the Cancer Anorexia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Cancer Anorexia Market Report: The Cancer Anorexia market size was valued approximately ~USD 310 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034) In November 2024, Endevica Bio's investigational peptide, designed to counteract cachexia-related weight loss, demonstrated significant benefits in preclinical rodent models of cancer chemotherapy. According to a study published in the Journal of Clinical Investigation, the peptide, TCMCB07 (B07), improved appetite while maintaining lean and fat mass. These findings highlight the promising potential of TCMCB07 to address chemotherapy-induced anorexia and weight loss, offering hope to millions of patients globally. In 2023, the US reported around 277,200 cases of cancer anorexia, with an expected increase throughout the forecast period. In the EU4 and the UK, Germany had the highest number of cancer anorexia incident cases, whereas Spain had the fewest. Lung cancer represents the highest number of anorexia incident cases among all cancer types, with approximately 150,300 cases in the US. The anticipated launch of promising therapies ART27.13 (Artelo Biosciences) and NGM120 (NGM Biopharmaceuticals) is expected to drive market growth in the coming years, supported by a rise in the incident population of cancer anorexia. Key Cancer Anorexia Companies: Helsinn Healthcare, Artelo Biosciences, NGM Biopharmaceuticals, and others Key Cancer Anorexia Therapies: ADLUMIZ/EDOLMIZU, Adlumiz, ART27.13, NGM120, and others The Cancer Anorexia epidemiology based on gender analyzed that Cancer Anorexia occurs in both men and women The Cancer Anorexia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cancer Anorexia pipeline products will significantly revolutionize the Cancer Anorexia market dynamics. Cancer Anorexia Overview The cancer anorexia-cachexia syndrome (CACS), which includes anorexia, is a common sign of intake is caused by a lack of appetite or a loss of desire to eat, however this alone cannot explain the complex changes that characterize the CACS. Get a Free sample for the Cancer Anorexia Market Report Cancer Anorexia Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Cancer Anorexia Epidemiology Segmentation: The Cancer Anorexia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Download the report to understand which factors are driving Cancer Anorexia epidemiology trends @ Cancer Anorexia Epidemiology Forecast Cancer Anorexia Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cancer Anorexia market or expected to get launched during the study period. The analysis covers Cancer Anorexia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Cancer Anorexia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Cancer Anorexia Therapies and Key Companies Discover more about therapies set to grab major Cancer Anorexia market share @ Cancer Anorexia Treatment Market Cancer Anorexia Market Drivers An increasing population of cancer patients with anorexia in the 7MM Scope of upcoming therapies Opportunity for novel treatments Presence of effective disease scoring system Cancer Anorexia Market Barriers Disease burden and impact on the quality of life Lack of knowledge about the condition The high mortality rate in cancer patients due to anorexia Scope of the Cancer Anorexia Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Cancer Anorexia Companies: Helsinn Healthcare, Artelo Biosciences, NGM Biopharmaceuticals, and others Key Cancer Anorexia Therapies: ADLUMIZ/EDOLMIZU, Adlumiz, ART27.13, NGM120, and others Cancer Anorexia Therapeutic Assessment: Cancer Anorexia current marketed and Cancer Anorexia emerging therapies Cancer Anorexia Market Dynamics: Cancer Anorexia market drivers and Cancer Anorexia market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Cancer Anorexia Unmet Needs, KOL's views, Analyst's views, Cancer Anorexia Market Access and Reimbursement Table of Contents 1. Cancer Anorexia Market Report Introduction 2. Executive Summary for Cancer Anorexia 3. SWOT analysis of Cancer Anorexia 4. Cancer Anorexia Patient Share (%) Overview at a Glance 5. Cancer Anorexia Market Overview at a Glance 6. Cancer Anorexia Disease Background and Overview 7. Cancer Anorexia Epidemiology and Patient Population 8. Country-Specific Patient Population of Cancer Anorexia 9. Cancer Anorexia Current Treatment and Medical Practices 10. Cancer Anorexia Unmet Needs 11. Cancer Anorexia Emerging Therapies 12. Cancer Anorexia Market Outlook 13. Country-Wise Cancer Anorexia Market Analysis (2020–2034) 14. Cancer Anorexia Market Access and Reimbursement of Therapies 15. Cancer Anorexia Market Drivers 16. Cancer Anorexia Market Barriers 17. Cancer Anorexia Appendix 18. Cancer Anorexia Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
